Deep Track Capital, LP

Q4 2021 13F Holdings Report, Stock Holdings

Signature - Title: Nir Messafi - CCO/CFO
Location: Greenwich, CT
Holdings as of: December 31, 2021
Value $: $1.35B
Num holdings: 49
Date filed: 2/14/2022, 09:39 AM
Form type: 13F-HR
Description: All US holdings of this investor are reported in this report. Top holdings included KROS, TVTX, BCYC, ISEE, and JAZZ.
Next filing: Q1 2022 - May 16, 2022
SEC: View on sec.gov
Options Holdings: Showing stock holdings, see here for options holdings

Sym	Weight	Company	Class	Value $	* Price $	Shares
KROS	5.62%	Keros Therapeutics Inc	COM	$76.1M	58.51	1.3M
TVTX	5.62%	Travere Therapeutics Inc	COM	$76M	31.04	2.45M
BCYC	4.95%	Bicycle Therapeutics Plc	SPONSORED ADS	$67M	60.87	1.1M
ISEE	4.94%	Iveric Bio Inc	COM	$66.9M	16.72	4M
JAZZ	4.71%	Jazz Pharmaceuticals Plc	SHS USD	$63.7M	127.40	500K
GBT	4.33%	Global Blood Therapeutics In	COM	$58.5M	29.27	2M
BEAM	4.12%	Beam Therapeutics Inc	COM	$55.8M	79.69	700K
CRNX	3.99%	Crinetics Pharmaceuticals In	COM	$54M	28.41	1.9M
RPTX	3.27%	Repare Therapeutics Inc	COM	$44.3M	21.09	2.1M
MDGL	3.13%	Madrigal Pharmaceuticals Inc	COM	$42.4M	84.74	500K
FDMT	3.08%	4 D Molecular Therapeutics In	COM	$41.7M	21.94	1.9M
NVCR	3.05%	Novocure Ltd	ORD SHS	$41.3M	75.08	550K
IMVT	3.01%	Immunovant Inc	COM	$40.7M	8.52	4.78M
KDNY	2.92%	Chinook Therapeutics Inc	COM	$39.5M	16.31	2.42M
KURA	2.64%	Kura Oncology Inc	COM	$35.7M	14.00	2.55M
DICE	2.51%	Dice Therapeutics Inc	COM	$33.9M	25.31	1.34M
JNCE	2.47%	Jounce Therapeutics Inc	COM	$33.4M	8.35	4M
ESPR	2.09%	Esperion Therapeutics Inc Ne	COM	$28.2M	5.00	5.64M
DYN	2.01%	Dyne Therapeutics Inc	COM	$27.3M	11.89	2.29M
VRDN	1.95%	Viridian Therapeutics Inc	COM	$26.4M	19.77	1.34M
FATE	1.81%	Fate Therapeutics Inc	COM	$24.5M	58.51	418K
RNA	1.76%	Avidity Biosciences Inc	COM	$23.8M	23.77	1M
GRTS	1.68%	Gritstone Bio Inc	COM	$22.8M	12.86	1.77M
SLN	1.68%	Silence Therapeutics Plc	ADS	$22.7M	23.89	951K
TCDAQ	1.65%	Tricida Inc	COM	$22.3M	9.56	2.34M
MGTA	1.59%	Magenta Therapeutics Inc	COM	$21.6M	4.43	4.87M
SAGE	1.57%	Sage Therapeutics Inc	COM	$21.3M	42.54	500K
PASG	1.51%	Passage Bio Inc	COM	$20.4M	6.35	3.22M
KALV	1.47%	Kalvista Pharmaceuticals Inc	COM	$19.8M	13.23	1.5M
NKTX	1.43%	Nkarta Inc	COM	$19.4M	15.35	1.26M
VERV	1.36%	Verve Therapeutics Inc	COM	$18.4M	36.87	500K
KRTX	1.26%	Karuna Therapeutics Inc	COM	$17.1M	131.00	130K
TNYA	1.07%	Tenaya Therapeutics Inc	COM	$14.4M	18.95	762K
PTGX	1.07%	Protagonist Therapeutics Inc	COM	$14.4M	34.20	422K
FULC	0.98%	Fulcrum Therapeutics Inc	COM	$13.3M	17.69	750K
SRRA	0.98%	Sierra Oncology Inc	COM NEW	$13.2M	21.74	608K
ABOS	0.97%	Acumen Pharmaceuticals Inc	COM	$13.1M	6.76	1.93M
ATRA	0.87%	Atara Biotherapeutics Inc	COM	$11.8M	15.76	750K
GHRS	0.86%	Gh Research Plc	ORDINARY SHARES	$11.7M	23.33	499K
ASND	0.8%	Ascendis Pharma A/S	SPONSORED ADR	$10.8M	134.53	80K
ATYR	0.61%	Atyr Pharma Inc	COM NEW	$8.22M	7.47	1.1M
VNDA	0.58%	Vanda Pharmaceuticals Inc	COM	$7.85M	15.69	500K
ASMB	0.52%	Assembly Biosciences Inc	COM	$6.99M	2.33	3M
CNTA	0.33%	Centessa Pharmaceuticals Plc	SPONSORED ADS	$4.5M	11.26	400K
AVRO	0.3%	Avrobio Inc	COM	$4.04M	3.85	1.05M
IPSC	0.29%	Century Therapeutics Inc	COM	$3.97M	15.86	250K
CNTB	0.25%	Connect Biopharma Hldgs Ltd	ADS	$3.33M	5.15	647K
ONCR	0.23%	Oncorus Inc	COM	$3.16M	5.27	600K
RFL	0.11%	Rafael Hldgs Inc	COM CL B	$1.46M	5.10	286K

Previous1Next

Showing 1 to 49 of 49 entries

Compare Q4 2021 to

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name	Title	City, State	Date
Nir Messafi	CCO/CFO	Greenwich, Connecticut	2/14/2022